Containing Discrete Coated Particles Pellets, Granules, Or Beads Patents (Class 424/458)
  • Publication number: 20090181081
    Abstract: Alterations of redox homeostasis in mammals underlie a host of symptoms, syndromes and diseases, including AIDS and cancer, which can be successfully treated by administration to a mammal of therapeutically-effective amounts of sulfide compounds and/or thiosulfate compounds and/or thionite compounds and/or sulfite compounds and/or thionate compounds and/or any organic, inorganic or organometallic precursors thereof. The unique compositions of this invention contain one or more “active sulfur compounds” in combination with each other or with other therapeutic agents. The invention also encompasses the varying modes of administration of the therapeutic compounds.
    Type: Application
    Filed: March 16, 2009
    Publication date: July 16, 2009
    Inventor: Gabriel Gojon-Romanillos
  • Publication number: 20090169618
    Abstract: The present invention provides extended release pharmaceutical compositions comprising zolpidem or a salt thereof.
    Type: Application
    Filed: December 29, 2008
    Publication date: July 2, 2009
    Inventors: Limor Ari-Pardo, Sivan Antler
  • Publication number: 20090169619
    Abstract: Extended release pharmaceutical dosage forms of carbamazepine for oral administration to maintain a patient's blood concentration for at least a 12 hour period, methods of administering dosage forms and processes for the preparation of such dosage form.
    Type: Application
    Filed: March 9, 2009
    Publication date: July 2, 2009
    Applicant: CorePharma LLC
    Inventors: Mukteeshwar Gande, Rasik Gondalia, Madhusudanarao Kothapalli, Naga Mahendar Velishala, Vamsi Koppuri
  • Publication number: 20090169617
    Abstract: A controlled-release formulation comprising one or more distinct and discrete units located in physical juxtaposition to enable administration to a patient in need of treatment in a single dose, characterised in that the or each unit comprise(s): (i) a unit dose of an active pharmaceutical ingredient or pharmaceutically acceptable salt thereof; (ii) one or more extended-release agent(s); and, optionally, (iii) one or more pharmaceutically acceptable excipients, wherein the sum of the unit dose(s) constitutes a pharmaceutically effective amount of the active pharmaceutical ingredient.
    Type: Application
    Filed: April 26, 2007
    Publication date: July 2, 2009
    Inventors: Panagiotis Keramidas, Brett Antony Mooney, Phillip John Ferguson
  • Patent number: 7544373
    Abstract: Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.
    Type: Grant
    Filed: April 2, 2007
    Date of Patent: June 9, 2009
    Assignee: Medicis Pharmaceutical Corporation
    Inventors: Mitchell Wortzman, R. Todd Plott, Kuljit Bhatia, Bhiku Patel
  • Patent number: 7541347
    Abstract: Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.
    Type: Grant
    Filed: April 2, 2007
    Date of Patent: June 2, 2009
    Assignee: Medicis Pharmaceutical Coropration
    Inventors: Mitchell Wortzman, R. Todd Plott, Kuljit Bhatia, Bhiku Patel
  • Publication number: 20090123536
    Abstract: The field of the present invention is that of oral pharmaceutical forms of losartan, and also treatments and administration methods relating thereto. The invention relates to the use, in an oral pharmaceutical form comprising losartan, of a coating or matrix including said losartan and allowing controlled release of said losartan, such that this form orally administered to a sample of individuals leads, irrespective of the fed or fasted state of the individuals, to a reduction of the interindividual standard deviation of the Cmax, which ensures lower variability of the efficacy and of the therapeutic safety of the pharmaceutical form relative to an immediate-release pharmaceutical form of losartan administered to this same sample of individuals, at the same dose. Another aim of the invention is to provide an oral pharmaceutical form of losartan that can be administered once a day and that is just as effective as the “one dose intake per day” forms and the “two dose intakes per day” forms.
    Type: Application
    Filed: February 21, 2006
    Publication date: May 14, 2009
    Applicant: Flamel Technologies, S.A.
    Inventors: Catherine Castan, Florence Guimberteau, Remi Meyrueix, Gerard Soula
  • Patent number: 7524515
    Abstract: Pharmaceutical safety dosage forms are provided which include a pharmaceutical and an antagonist to the pharmaceutical. The safety dosage forms are such that the antagonist has no significant bioavailability when the pharmaceutical safety dosage form is administered as intended. However, the antagonist is released and becomes bioavailable if the dosage form is disrupted. Methods of administering pharmaceuticals by providing pharmaceutical safety dosage forms are also provided.
    Type: Grant
    Filed: January 10, 2003
    Date of Patent: April 28, 2009
    Assignee: Mutual Pharmaceuticals, Inc.
    Inventor: Richard H. Roberts
  • Publication number: 20090092658
    Abstract: The present invention relates to combinations of a proton pump inhibiting agent and at least one buffering agent that have been found to possess improved bioavailability, chemical stability, physical stability, dissolution profiles, disintegration times, as well as other improved pharmacokinetic, pharmacodynamic, chemical and/or physical properties.
    Type: Application
    Filed: October 5, 2007
    Publication date: April 9, 2009
    Inventors: Warren Hall, Laura Weston, Kay Olmstead, Laura Gallo, Craig Bowe
  • Publication number: 20090060994
    Abstract: A solid dosage form for oral administration comprising azithromycin in an amount below that which causes gastrointestinal side effects, which dosage form is a controlled release dosage form.
    Type: Application
    Filed: December 17, 2007
    Publication date: March 5, 2009
    Inventors: Radhakrishnan Pillai, Pramod Sarpotdar, David W. Osborne, Gordon J. Dow
  • Patent number: 7470435
    Abstract: A controlled release dosage form of venlafaxine that comprises an immediate release pellet and an extended release pellet.
    Type: Grant
    Filed: November 17, 2003
    Date of Patent: December 30, 2008
    Assignee: Andrx Pharmaceuticals, LLC
    Inventors: Manesh Dixit, Xiu-Xiu Cheng, Avinash Nangia, Chih Ming Chen
  • Publication number: 20080317846
    Abstract: A unit dosage form, such as a capsule or the like, for delivering drugs into the body in a circadian release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. Each bead population exhibits a pre-designed rapid or sustained release profile with or without a predetermined lag time of 3 to 5 hours. Such a circadian rhythm release drug delivery system is designed to provide a plasma concentration-time profile, which varies according to physiological need at different times during the dosing period, i.e., mimicking the circadian rhythm and severity/manifestation of gastric acid secretion (and/or midnight gerd), predicted based on pharmaco-kinetic and pharmaco-dynamic considerations and in vitro/in vivo correlations.
    Type: Application
    Filed: July 11, 2008
    Publication date: December 25, 2008
    Inventors: Phillip J. Percel, Nehal H. Vyas, Krishna S. Vishnupad, Gopi M. Venkatesh
  • Patent number: 7455864
    Abstract: A method for improving sleep in an individual comprising the administration of a composition comprising melatonin, lavender flower extract and Ferula extract is provided. The composition may be in a layered solid dosage form to provide controlled and sustained release of specific ingredients.
    Type: Grant
    Filed: June 4, 2007
    Date of Patent: November 25, 2008
    Assignee: Iomedix Development International Srl
    Inventors: Marvin Heuer, Ken Clement, Shan Chaudhuri, Megan Thomas
  • Publication number: 20080268043
    Abstract: The invention relates to a formulation for the treatment of acute manic episodes associated with Bipolar I Disorder comprising an antipsychotic agent selected from the group consisting of: a dibenzothiazepine derivative; lithium; and divalproex. The formulation comprises a first component which comprises a first population the antipsychotic agent and at least one subsequent component which comprises a subsequent population of the antipsychotic agent and which allows for the modified release of the agent. The combination of the first and the subsequent components in operation deliver the antipsychotic agent in a pulsed or controlled manner over a period of up to twenty-four hours.
    Type: Application
    Filed: January 26, 2006
    Publication date: October 30, 2008
    Applicant: ELAN PHARMA INTERNATIONAL LIMITED
    Inventors: Scott A Jenkins, Gary Liversidge
  • Publication number: 20080260819
    Abstract: A sustained release pharmaceutical composition has been developed. The composition resists dose dumping when broken, crushed or chewed, which enhances the safety of the dosage form should it be accidentally or intentionally physically compromised. In the preferred embodiment, a drug is modified to increase its lipophilicity. In preferred embodiments the modified drug is homogeneously dispersed within microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles coated with one or more coating layers. The sustained release composition retards the release of drug, even if the physical integrity of the formulation is compromised (for example, by chewing or crushing) and the resulting material is placed in 0.1N HCl.
    Type: Application
    Filed: April 30, 2008
    Publication date: October 23, 2008
    Inventors: Alison B. Fleming, Roman V. Rariy, Jane Hirsh, Alexander M. Klibanov
  • Publication number: 20080248103
    Abstract: A method for improving sleep in an individual comprising the administration of a composition comprising melatonin, lavender flower extract and Ferula extract is provided. The composition may be in a layered solid dosage form to provide controlled and sustained release of specific ingredients.
    Type: Application
    Filed: June 4, 2007
    Publication date: October 9, 2008
    Applicant: IOMEDIX DEVELOPMENT INTERNATIONAL SRL
    Inventors: Marvin HEUER, Ken CLEMENT, Shan CHAUDHURI, Megan THOMAS
  • Publication number: 20080248107
    Abstract: The present invention provides a controlled release formulation comprising an therapeutically effective amount of pharmacologically active substance having high water solubility, at least one non-polymeric release retardant, and at least one pH independent non-swelling release retarding polymer. The said dosage form provides controlled release of the active agent with reduced initial burst release.
    Type: Application
    Filed: August 24, 2006
    Publication date: October 9, 2008
    Applicant: Rubicon Research Pvt. Ltd.
    Inventors: Pratibha S. Pilgaonkar, Maharukh T. Rustomjee, Anikumar S. Gandhi, Atul A. Kelkar, Pradnya Bagde
  • Patent number: 7431944
    Abstract: Dosage forms for oral administration of a methylphenidate drug are provided. The dosage forms provide a substantially immediate dose of methylphenidate upon ingestion, followed by one or more additional doses at predetermined times. By providing such a drug release profile, the dosage forms eliminate the need for a patient to carry an additional dose for ingestion during the day. The dosage forms and methods provided are useful in administering methylphenidate and pharmaceutically acceptable salts thereof, which generally require one or more doses throughout the day.
    Type: Grant
    Filed: June 10, 2003
    Date of Patent: October 7, 2008
    Assignee: Celgene Corporation
    Inventors: Atul M. Mehta, Andrew L. Zeitlin, Maghsoud M. Dariani
  • Patent number: 7427413
    Abstract: The present invention provides storage stable, shaped particles of allotropic organic compounds. The particles of the present invention can be shaped according to the desired application. Preferred shapes of such particles are microspheres, particularly those having diameters of about 1 to about 1,000 microns. The stable shaped particles of the present invention are particularly well-suited to the fabrication of pharmaceutical formulations, particularly where sustained release and uniform bioavailability are desired. The storage stable particles are formed by a solid state crystallization of allotropic organic compounds. The solid state crystallization process of the present invention affords a means for achieving a storage stable crystalline form of said allotropic compound without loss or deterioration of the original particle dimensions.
    Type: Grant
    Filed: February 26, 2003
    Date of Patent: September 23, 2008
    Assignee: Skendi Finance Ltd.
    Inventors: John-Claude Savoir, Juan Angeles, Aurelio De Gyves, Abraham Gomez
  • Publication number: 20080226712
    Abstract: The invention relates to an oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles and their salts, which comprises the active compound together with tablet disintegrants and is provided with a film coating customary per se for sustained-release compositions.
    Type: Application
    Filed: May 21, 2008
    Publication date: September 18, 2008
    Applicant: NYCOMED GmbH
    Inventors: Rango Dietrich, Hartmut Ney
  • Patent number: 7422758
    Abstract: A therapeutic formulation in the form of a beadlet, suitable for oral administration and adapted to provide immediate and sustained release of therapeutic material. Each beadlet comprises an extruded-spheronized inner core containing at least one medicament e.g. a slow release vitamin, an outer layer containing at least one medicament e.g. a fast release vitamin and a controlled release coating between the inner core and the outer layer which coating controls the release of the inner core medicament.
    Type: Grant
    Filed: March 21, 2001
    Date of Patent: September 9, 2008
    Assignees: GlaxoSmithKline Consumer Healthcare GmbH & Co. KG, Allphamed Pharbil Pharma GmbH
    Inventors: Juergen Block, Stefan Heim, Ralf Westerheide
  • Patent number: 7419686
    Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).
    Type: Grant
    Filed: December 26, 2006
    Date of Patent: September 2, 2008
    Assignee: Purdue Pharma L.P.
    Inventors: Robert F. Kaiko, Robert D. Colucci
  • Publication number: 20080175903
    Abstract: The present disclosure provides a unit dosage form with an anxiolytic dosage of zopiclone particularly eszopiclone. Also provided is a method for treatment or prophylaxis of anxiety using a subsedative dosage of zopiclone particularly eszopiclone.
    Type: Application
    Filed: December 1, 2007
    Publication date: July 24, 2008
    Applicant: Sepracor Inc.
    Inventors: Seth C. Hopkins, Mark A. Varney, Tushar Misra, Gary Maier, Judy Caron, Randall S. Wagner
  • Patent number: 7387791
    Abstract: This invention comprises pharmaceutical compositions for administering a biologically active compound to an animal. Particularly provided are proliposomal compositions that are advantageously used to deliver biologically active compounds to the gastrointestinal tract after oral administration.
    Type: Grant
    Filed: July 13, 2004
    Date of Patent: June 17, 2008
    Assignee: Oradel Medical Ltd.
    Inventors: Guru V. Betageri, Milton B. Yatvin
  • Patent number: 7384653
    Abstract: The present invention provides an oral dosage form comprising a first composition and a second composition. The first composition comprises an effective amount of a therapeutic agent and the second composition comprises an effective amount of an adverse-effect agent. The adverse-effect agent is covered with a coating that is substantially insoluble in the gastrointestinal tract. In one embodiment, the adverse-effect agent is coated with an outer base-soluble layer and an inner acid-soluble layer. The therapeutic agent can be uncoated or can be coated with a coating having an outer acid-soluble layer and an inner base-soluble layer. The dosage form discourages administration of the therapeutic agent by other than oral administration.
    Type: Grant
    Filed: September 23, 2004
    Date of Patent: June 10, 2008
    Assignee: Purdue Pharma L.P.
    Inventors: Curtis Wright, IV, Anthony E. Carpanzano
  • Publication number: 20080118557
    Abstract: Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.
    Type: Application
    Filed: November 16, 2007
    Publication date: May 22, 2008
    Inventors: Likan Liang, Hua Wang, Padmanabh P. Bhatt, Michael L. Vieira
  • Patent number: 7374781
    Abstract: A sustained release formulation as a unit dose contains 100 mg-1000 mg of Acetaminophen and 15 mg-150 mg of tramadol hydrochloride, which comprises of 1) an immediate release portion comprising of 25%-75% of the total effective amount of drug in the dosage form and 2) a sustained release portion comprising of a) 25%-75% of the total effective amount of drugs in the dosage form; b) 6%-50% of gelling polymers of the total formulation, and c) optionally an enteric coating at a level of 5%-40% of the total formulation. The set forth formulation dissolves 25%-60% of the total drug in the first hour, 50%-90% of the total drug in the first four hours and not less than 80% of the total drug in the first 12 hours using USP dissolution method II at 50 rpm.
    Type: Grant
    Filed: September 20, 2003
    Date of Patent: May 20, 2008
    Inventors: Shuyi Zhang, Jin Wang
  • Patent number: 7348026
    Abstract: The invention discloses the nanoparticles composed of ?-PGA-PLA block copolymers conjugated with galactosamine as a potential drug delivery system for treating liver cancers.
    Type: Grant
    Filed: October 5, 2004
    Date of Patent: March 25, 2008
    Inventors: Hsing-Wen Sung, Hsiang-Fa Liang, Ting-Fan Yang, Chin-Tsung Huang, Hosheng Tu
  • Patent number: 7320802
    Abstract: The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.
    Type: Grant
    Filed: October 27, 2003
    Date of Patent: January 22, 2008
    Assignees: Elan Pharma International, Ltd., Fournier Laboratories Ireland Ltd.
    Inventors: Tuula Ryde, Evan E. Gustow, Stephen B. Ruddy, Rajeev Jain, Rakesh Patel, Michael John Wilkins
  • Patent number: 7316818
    Abstract: This invention comprises pharmaceutical compositions for administering a polycyclic, aromatic, antioxidant or anti-inflammatory compound to an animal. Particularly provided are proliposomal compositions that are advantageously used to deliver polycyclic, aromatic, antioxidant or anti-inflammatory compounds to the gastrointestinal tract after oral administration.
    Type: Grant
    Filed: November 30, 2004
    Date of Patent: January 8, 2008
    Assignee: Oradel Medical Ltd.
    Inventor: Milton Yatvin
  • Patent number: 7314640
    Abstract: The present invention relates to a controlled release pellet of metoprolol and its pharmaceutically acceptable salts that uses a water soluble or a water swellable inert starting seed or core.
    Type: Grant
    Filed: July 11, 2003
    Date of Patent: January 1, 2008
    Inventors: Mongkol Sriwongjanya, Samuel Yuk, Avinash Nangia
  • Patent number: 7303765
    Abstract: L-carnitine which has a particle size such that it substantially passes through a 100 USBS mesh sieve exhibits an increased bioavailability, a decreased hygroscopicity, and may be conveniently formulated with oil-based materials.
    Type: Grant
    Filed: January 25, 2005
    Date of Patent: December 4, 2007
    Assignee: Sigma-Tau HealthScience S.p.A.
    Inventor: Ken Hassan
  • Patent number: 7276249
    Abstract: The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.
    Type: Grant
    Filed: May 23, 2003
    Date of Patent: October 2, 2007
    Assignees: Elan Pharma International, Ltd., Fournier Laboratories Ireland Ltd.
    Inventors: Tuula Ryde, Evan E. Gustow, Stephen B. Ruddy, Rajeev Jain, Rakesh Patel, Michael John Wilkins
  • Publication number: 20070218126
    Abstract: Compositions and methods for reducing inflammation and pain associated with acidosis. One embodiment of the composition comprises a plurality of carrier particles, wherein the plurality of carrier particles hold a plurality of alkaline compounds, and wherein the alkaline compounds can be delivered to, and absorbed across, lipid membranes into the blood stream in small quantities over an extended period of time.
    Type: Application
    Filed: March 16, 2007
    Publication date: September 20, 2007
    Applicant: Tamer Laboratories, Inc.
    Inventors: Macit Gurol, Robert Burns, Candace McNaughton
  • Publication number: 20070202162
    Abstract: The present invention relates to extended release pharmaceutical compositions comprising a beta-blocker drug or a pharmaceutically acceptable salt thereof, wherein said composition comprises at least two extended release portions, each portion having an in vitro dissolution profile that is different from another portion.
    Type: Application
    Filed: February 23, 2007
    Publication date: August 30, 2007
    Inventors: Anand Sankarnarayanan, Subhash Pandurang Gore, Ravinder Kodipyaka, Indu Bhushan, Mailatur Sivaraman Mohan
  • Patent number: 7217431
    Abstract: A process for the preparation of a particulate material by a controlled agglomeration method, i.e. a method that enables a controlled growth in particle size. The method is especially suitable for use in the preparation of pharmaceutical compositions containing a therapeutically and/or prophylactically active substance which has a relatively low aqueous solubility and/or which is subject to chemical decomposition. The process comprising i) spraying a first composition comprising a carrier, which has a melting point of about 5° C. or more which is present in the first composition in liquid form, on a second composition comprising a material in solid form, the second composition having a temperature of at the most a temperature corresponding to the melting point of the carrier and/or the carrier composition and ii) mixing or others means of mechanical working the second composition onto which the first composition is sprayed to obtain the particulate material.
    Type: Grant
    Filed: July 5, 2002
    Date of Patent: May 15, 2007
    Assignee: LifeCycle Pharma A/S
    Inventors: Per Holm, Anders Buur, Michiel Onne Elema, Birgitte Møllgaard, Jannie Egeskov Holm, Kirsten Schultz
  • Patent number: 7211275
    Abstract: Composite materials comprising a water-soluble compound adsorbed onto a basic inorganic material and a bio-degradable polymer which yields acidic degradation products, methods of producing same, and methods of use thereof are described, wherein the composite materials are designed so as to provide controlled release of the water soluble molecule.
    Type: Grant
    Filed: January 13, 2005
    Date of Patent: May 1, 2007
    Assignee: Massachusetts Institute of Technology
    Inventors: Jackie Y. Ying, Tseh-Hwan Yong
  • Patent number: 7208460
    Abstract: The present invention relates to an improved controlled delivery system that can be incorporated in soap bars to enhance deposition of active ingredients and sensory markers onto skin. The carrier system also provides controlled release or prolonged release of these actives from the skin over an extended period of time. The controlled delivery system of the present invention comprises substantially free-flowing, powder formed of solid hydrophobic, positively charged, nanospheres of encapsulated active ingredients, that are encapsulated in moisture sensitive microspheres. The high cationic charge density of the nanosphere improves deposition of active ingredients onto skin.
    Type: Grant
    Filed: September 24, 2004
    Date of Patent: April 24, 2007
    Assignee: Salvona IP, LLC
    Inventors: Adi Shefer, Samuel Shefer
  • Patent number: 7195769
    Abstract: A pharmaceutical composition of anti-tubercular drugs for oral use comprising Rifampicin and/or Isoniazid wherein the bioavailability of Rifampicin and/or other drugs is enhanced. Preferably the bioavailability of Rifampicin is enhanced by preventing its degradation caused by presence of Isoniazid. Rifampicin and/or Isoniazid may be present in delayed release and/or extended release form such that minimal amount of the drug is dissolved between pH 1 and 4. preferably delayed release of Rifampicin and/or Isoniazid is achieved by treating the drugs with pH sensitive polymers.
    Type: Grant
    Filed: April 10, 2001
    Date of Patent: March 27, 2007
    Assignee: Panacea Biotec Limited
    Inventors: Amarjit Singh, Rajesh Jain
  • Patent number: 7186418
    Abstract: The invention provides compositions comprising an RAR antagonist for promoting chondrogenesis and methods employing such compositions for treating cartilage and associated bone abnormalities resulting from injury or disease and for ex vivo tissue engineering.
    Type: Grant
    Filed: November 19, 1999
    Date of Patent: March 6, 2007
    Assignee: University of Western Ontario
    Inventors: Tully Michael Underhill, Andrea Dawn Weston
  • Patent number: 7157103
    Abstract: Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse; and an effective amount of an irritant to impart an irritating sensation to an abuser upon administration of said dosage form after tampering.
    Type: Grant
    Filed: August 6, 2002
    Date of Patent: January 2, 2007
    Assignee: Euro-Celtique S.A.
    Inventor: Richard Sackler
  • Patent number: 7153840
    Abstract: This invention is directed towards a ready-to-use aqueous composition of fludarabine phosphate. In one embodiment, the invention is directed to an aqueous fludarabine phosphate composition which comprises fludarabine phosphate, a base, and water. The concentration of fludarabine phosphate in the composition may be between about 0.5 mg/mL and about 50 mg/mL. The pH of the composition may be between about 5.5 and about 7.1.
    Type: Grant
    Filed: May 23, 2003
    Date of Patent: December 26, 2006
    Assignee: Sicor, Inc.
    Inventors: Dorla Mirejovsky, Peter Lindsay Macdonald
  • Patent number: 7148207
    Abstract: This invention relates to a quick-release tablet formulation with >99.19% pure fludara (high-purity fludara) as an active ingredient in a defined composition of residual contaminants.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: December 12, 2006
    Assignee: Schering Aktiengesellschaft
    Inventors: Wolfgang Heil, Ulf Tistam, Ralph Lipp, Johannes-Wilhelm Tack
  • Patent number: 7144587
    Abstract: Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic; an opioid antagonist; and a bittering agent in an effective amount to impart a bitter taste to an abuser upon administration of the dosage form after tampering.
    Type: Grant
    Filed: August 6, 2002
    Date of Patent: December 5, 2006
    Assignee: Euro-Celtique S.A.
    Inventors: Benjamin Oshlack, Robert Colucci, Curtis Wright, Christopher Breder
  • Patent number: 7141250
    Abstract: Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse; and an effective amount of a bittering agent to impart a bitter taste to an abuser upon administration of said dosage form after tampering.
    Type: Grant
    Filed: August 6, 2002
    Date of Patent: November 28, 2006
    Assignee: Euro-Celtique S.A.
    Inventors: Benjamin Oshlack, Robert Colucci, Curtis Wright, Christopher Breder
  • Patent number: 7122207
    Abstract: A high drug load spheronized beadlet is provided wherein said beadlet comprises about 80% to 100% by weight of an acid labile medicament, preferably didanosine, about 0% to about 10% by weight of a disintegrant, and about 0% to about 10% by weight of a binder selected from the group consisting of sodium carboxymethylcellulose, hydroxypropylmethylcellulose, potassium alginate, and partially pregelatinized corn starch. A high drug load pharmaceutical composition, comprising the beadlet, with an enteric coating disposed thereon, is also provided.
    Type: Grant
    Filed: May 3, 2001
    Date of Patent: October 17, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ismat Ullah, Gary J Wiley
  • Patent number: 7108866
    Abstract: A controlled-release Galenical preparation of pharmaceutically acceptable Diltiazem including the pharmaceutically acceptable salts thereof, suitable for evening dosing every 24 hours containing from about 120 mg to about 540 mg or more (as desired) of the form of Diltiazem associated with excipients to provide controlled (sustained) release of the form of Diltiazem for providing a Cmax of Diltiazem in the blood at between about 10 hours and about 15 hours after administration, the preparation comprising the form of Diltiazem in oral sustained-release dosage form in which the Diltiazem is adapted to be released after administration over a prolonged period of time and exhibits when given to humans (i) a higher bioavailability when given at night compared to when given in the morning without food according to FDA guidelines or criteria and (ii) bioequivalence when given in the morning with and without food according to the same FDA guidelines or criteria.
    Type: Grant
    Filed: May 8, 2000
    Date of Patent: September 19, 2006
    Assignee: Biovall Laboratories International SRL
    Inventors: Kenneth Stephen Albert, Paul José Maes
  • Patent number: 7087249
    Abstract: The invention relates to the use of one or more antimicrobial metals preferably selected from silver, gold, platinum, and palladium but most preferably silver, formed with atomic disorder, and preferably in a nanocrystalline form, for reducing inflammation or infection of the mucosal membrane. The antimicrobial metal may be formulated as, or used in the form of, a nanocrystalline coating of one or more antimicrobial or noble metals, a nanocrystalline powder of one or more antimicrobial or noble metals, or a liquid or solution containing dissolved species from a nanocrystalline powder or coating of one or more antimicrobial or noble metals.
    Type: Grant
    Filed: April 23, 2002
    Date of Patent: August 8, 2006
    Assignee: Nucryst Pharmaceuticals Corp.
    Inventors: Robert Edward Burrell, Antony George Naylor, Peter Howard Moxham
  • Patent number: RE39239
    Abstract: The present invention provides methods of treating early morning pathologies using a time-specific controlled release dosage formulation which is administered prior to sleep, and which permits or achieves delivery of a pharmaceutically active agent effective for the treatment of the specific early morning pathology to be treated, at about the time of awakening. The time-specific controlled release dosage formulation comprises (1) a core including the pharmaceutically active agent(s) effective for the treatment of the early morning pathology, and (2) a swellable polymeric coating layer substantially surrounding the core. The swellable polymeric coating layer delays the release of the pharmaceutically active agent from the core for a predetermined period of time dependent upon the thickness of the swellable polymeric coating layer, to effect delivery of the pharmaceutically active agent at about the time of awakening.
    Type: Grant
    Filed: September 17, 2002
    Date of Patent: August 15, 2006
    Assignee: Polichem SA
    Inventors: Cesare Busetti, Tiziano Crimella
  • Patent number: RE40300
    Abstract: The present invention provides a method of increasing the deposition of aerosolized drug in the respiratory tract of an individual or animal, comprising the step of administering said aerosolized drug in an air mixture containing up to about 10% carbon dioxide gas.
    Type: Grant
    Filed: August 26, 2004
    Date of Patent: May 6, 2008
    Assignee: Research Development Foundation
    Inventors: J. Clifford Waldrep, J. Vernon Knight, Nadezhda Koshkina